文献速递淋巴瘤

微环境诱导的CD44v6促进慢性淋巴细胞白血病早期疾病进展

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2018-01-19

该研究在B细胞特异性CD44缺陷的Tcl1转基因小鼠中确定标准CD44及其变异体在白血病B细胞归巢和增殖中的体内作用,发现白血病发病延迟且脾、肝、肺(而非骨髓)的白血病浸润减少。竞争性移植显示CLL归巢至脾和骨髓需要功能性CD44,脾中CD44v6变异体富集增强CLL植入和增殖并增加透明质酸结合。研究在人类疾病中重现CD44v6诱导,并揭示CD40配体和B细胞受体刺激下MAPK和NF-κB信号参与。

要点

  • CD44缺陷延迟白血病发病并减少脾、肝、肺浸润,但不减少骨髓浸润。
  • CLL归巢至脾和骨髓需要功能性CD44。
  • 脾中CD44v6富集增强CLL植入和增殖,并增加透明质酸结合。

核心结论

  • 研究提出CLL中存在CD44-NF-κB-CD44v6回路,使肿瘤细胞获得透明质酸结合能力并支持其增殖。

研究设计与样本

  • 研究使用B细胞特异性CD44缺陷的Tcl1转基因小鼠,并进行竞争性移植、体外抑制实验和染色质免疫沉淀实验。

主要发现

  • 在CD44缺陷小鼠中,白血病发病延迟,脾、肝和肺的白血病浸润减少,但骨髓浸润未减少。
  • 竞争性移植显示CLL归巢至脾和骨髓需要功能性CD44。
  • 脾中CD44v6变异体富集增强CLL植入和增殖,并增加透明质酸结合。
  • 在人类疾病中重现CD44v6诱导,体外抑制实验和染色质免疫沉淀实验揭示CD40配体和B细胞受体刺激下MAPK和NF-κB信号参与。
  • CD44v6与透明质酸结合后下游信号检测到细胞外信号调节激酶和p65激活。

临床怎么用

  • 抗CD44v6治疗在体外减少人和小鼠的白血病细胞增殖,证实了研究发现的普遍性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) outgrowth depends on signals from the microenvironment. We have previously found that in vitro reconstitution of this microenvironment induces specific variant isoforms of the adhesion molecule CD44, which confer human CLL with high affinity to hyaluronan (HA). Here, we determined the in vivo contribution of standard CD44 and its variants to leukemic B-cell homing and proliferation in Tcl1 transgenic mice with a B-cell-specific CD44 deficiency. In these mice, leukemia onset was delayed and leukemic infiltration of spleen, liver, and lungs, but not of bone marrow, was decreased. Competitive transplantation revealed that CLL homing to spleen and bone marrow required functional CD44. Notably, enrichment of CD44v6 variants particularly in spleen enhanced CLL engraftment and proliferation, along with increased HA binding. We recapitulated CD44v6 induction in the human disease and revealed the involvement of MAPK and NF-κB signaling upon CD40 ligand and B-cell receptor stimulation by in vitro inhibition experiments and chromatin immunoprecipitation assays. The investigation of downstream signaling after CD44v6-HA engagement uncovered the activation of extracellular signal-regulated kinase and p65. Consequently, anti-CD44v6 treatment reduced leukemic cell proliferation in vitro in human and mouse, confirming the general nature of the findings. In summary, we propose a CD44-NF-κB-CD44v6 circuit in CLL, allowing tumor cells to gain HA binding capacity and supporting their proliferation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gutjahr JC, Szenes E, Tschech L, et al. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood. 2018. PMID: 29352038. doi:10.1182/blood-2017-08-802462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。